Valuation: BioRestorative Therapies, Inc.

Market Cap 8.51M 7.44M 6.86M 6.33M 11.93M 820M 12.19M 82.05M 32.27M 401M 31.97M 31.27M 1.38B P/E 2026 *
-0.67x
P/E 2027 * -0.82x
Enterprise Value 8.51M 7.44M 6.86M 6.33M 11.93M 820M 12.19M 82.05M 32.27M 401M 31.97M 31.27M 1.38B EV / Sales 2026 *
6.06x
EV / Sales 2027 * 3.68x
Free-Float
87.87%
Yield 2026 *
-
Yield 2027 * -
1 day-4.76%
1 week-3.16%
Current month-11.14%
1 month-18.43%
3 months+26.70%
6 months-70.95%
Current year-71.57%
1 week 0.32
Extreme 0.32
0.37
1 month 0.32
Extreme 0.32
0.43
Current year 0.16
Extreme 0.1593
1.28
1 year 0.16
Extreme 0.1593
1.89
3 years 0.16
Extreme 0.1593
3.67
5 years 0.16
Extreme 0.1593
26.8
10 years 0.16
Extreme 0.1593
20,040
Manager TitleAgeSince
Chief Executive Officer 55 2020-11-15
Director of Finance/CFO 59 2021-11-03
Investor Relations Contact - -
Director TitleAgeSince
Chairman 55 2020-11-15
Director/Board Member 61 2021-10-28
Director/Board Member 28 2026-06-11
Date Insider Type Main position Quantity % Market Cap.
10/6/25 Free

Chief Executive Officer

27,344 0.3427%
10/6/25 Free

Chief Technology Officer

23,438 0.2938%
2/14/25 Other

Chief Technology Officer

768,979 11.1125%
Change 5-day change 1-year change 3-year change Capi.($)
-4.76%-3.16%-78.72%-89.22% 8.51M
+0.24%-1.54%+52.85%+71.85% 53.83B
-7.17%-4.39%+42.72%+73.32% 52.1B
+0.80%-6.31%+5.62%+417.78% 23.48B
-0.09%-0.01%-16.85%-15.41% 23.13B
-5.95%-2.58%+29.53%-9.47% 19.36B
-1.14%+0.03%+31.67%-30.65% 17.56B
-5.16%-7.00%+168.44%+314.96% 15.2B
-6.91%-5.83%+25.17%+644.30% 14.83B
+0.43%-1.03%+25.75%+189.74% 14.06B
Average -2.97%-2.68%+28.62%+156.72% 23.36B
Weighted average by Cap. -2.80%-2.36%+39.54%+143.12%

Financials

2026 *2027 *
Net sales 1.4M 1.23M 1.13M 1.04M 1.97M 135M 2.01M 13.54M 5.33M 66.27M 5.28M 5.16M 228M 2.31M 2.02M 1.86M 1.72M 3.24M 223M 3.31M 22.29M 8.77M 109M 8.68M 8.49M 375M
Net income -13.52M -11.82M -10.91M -10.05M -18.95M -1.3B -19.37M -130M -51.27M -638M -50.79M -49.67M -2.2B -15.56M -13.6M -12.55M -11.56M -21.8M -1.5B -22.28M -150M -58.98M -734M -58.43M -57.15M -2.53B
Net Debt - -
Logo BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
Employees
14
Date Price Change Volume
26-07-17 $0.3341 -4.76% 160,032
26-07-16 $0.3508 +3.18% 605,904
26-07-15 $0.3400 +3.03% 54,873
26-07-14 $0.3300 -2.42% 359,586
26-07-13 $0.3382 -1.97% 187,031
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.3341USD
Average target price
8.000USD
Spread / Average Target
+2,294.49%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BRTX Stock